ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

WuXi’s STA unit opens oligonucleotide plant

by Rick Mullin
January 10, 2020 | APPEARED IN VOLUME 98, ISSUE 2

 

09802-buscon14-oligos.jpg
Credit: WuXi AppTec
The production room at WuXi's new oligonucleotide plant

STA Pharmaceutical, the active pharmaceutical ingredient (API) manufacturing arm of WuXi AppTec, has opened a large-scale oligonucleotide API plant in Changzhou, China. The 2,800 m2 facility is designed to make up to 1 mol per synthesis run. STA says its oligo platform covers modalities including DNA, RNA, Morpholino oligonucleotides, and peptide conjugates.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment